Sandoz Group AG (SWX: SDZ) is a global leader in generics and biosimilars, recently spun off from Novartis to operate as an independent company. It focuses on making essential medicines more accessible while expanding its biosimilar pipeline. Sandoz’s shares are influenced by pricing dynamics in generics, regulatory approvals, and growth in its high-margin biosimilar segment.